Introduction Since 2006, the human papillomavirus (HPV) vaccine has been recommended
for females aged 9–26 years in the United States. Aiming to evaluate the early effect of the …

Background: To date, the impact of the human papillomavirus (HPV) vaccine on invasive
cervical cancers in the United States has not been documented due, in part, to the time …

Introduction Since 2006, human papillomavirus vaccine has been recommended for young
females in the US This study aimed to compare cervical cancer incidence among young …

Background The primary goal of human papillomavirus (HPV) vaccination is to reduce
morbidity and mortality from HPV-associated disease, especially cervical cancer. We …

The first prophylactic vaccine against human papillomavirus (HPV) 16 and HPV18 was
licensed in Japan in 2009. HPV vaccine effectiveness against high‐grade cervical lesions …

Simple Summary Human papillomavirus (HPV) vaccination disparities between urban and
rural regions may moderate the vaccine's impact on reducing cervical precancer (CIN2+) …

Background: Human papillomavirus (HPV) is a sexually transmitted infection, and HPV types
16 and 18 are responsible for approximately 66% of all US cervical cancer cases in women …

Background Although new human papillomavirus (HPV) infections can occur at all ages, the
age at which women acquire their “causal” HPV infection that develops into cervical cancer …

Background Trends in human papillomavirus (HPV)–associated cervical lesions can provide
an indication of vaccine impact. Our purpose was to measure trends in cervical lesions …

Introduction Demonstrating human papillomavirus vaccine impact is critical for informing
guidelines to increase vaccination and decrease human papillomavirus‒related outcomes …